Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 212, Issue 10, Pages 1679-1692Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20150489
Keywords
-
Categories
Funding
- National Institutes of Health [RO1AI079243]
- National Research Service Award [CA183220, HL110691]
- UCLA/Caltech Medical Scientist Training Program
- Human Frontiers Science Foundation
Ask authors/readers for more resources
MicroRNAs have emerged as key regulators of B cell fate decisions and immune function. Deregulation of several microRNAs in B cells leads to the development of autoimmune disease and cancer in mice. We demonstrate that the microRNA-212/132 cluster (miR-212/132) is induced in B cells in response to B cell receptor signaling. Enforced expression of miR-132 results in a block in early B cell development at the prepro-B cell to pro-B cell transition and induces apoptosis in primary bone marrow B cells. Importantly, loss of miR-212/132 results in accelerated B cell recovery after antibody-mediated B cell depletion. We find that Sox4 is a target of miR-132 in B cells. Co-expression of SOX4 with miR-132 rescues the defect in B cell development from overexpression of miR-132 alone, thus suggesting that miR-132 may regulate B lymphopoiesis through Sox4. In addition, we show that the expression of miR-132 can inhibit cancer development in cells that are prone to B cell cancers, such as B cells expressing the c-Myc oncogene. We have thus uncovered miR-132 as a novel contributor to B cell development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available